#biotech

A $7M quantum computing competition is testing whether today's noisy, limited quantum machines can actually help human health—before the powerful ones we've been promised ever arrive.

Japan approves world's first commercial iPS cell therapies for heart disease and Parkinson's. A breakthrough that could reshape medicine globally, but questions remain about accessibility and competition.

New research shows DMT can treat depression in 15 minutes without hallucinations. Could this fast-acting psychedelic revolutionize mental healthcare and challenge Big Pharma's dominance?

Trump's NIH pushes to end primate research at major university centers, sparking debate over animal testing vs. cutting-edge alternatives in medical research.

Former fintech founder Bryan Johnson sells immortality program for $1M annually. Only three spots available. The ultra-wealthy longevity craze examined.

Life extension technologies are becoming exclusive to the wealthy, raising profound questions about inequality and the commodification of human longevity.

The Vitalism movement, which considers death humanity's core problem, is gaining political influence in the US government, pushing for policy changes to advance longevity research and experimental drug access.

How the Vitalism movement is infiltrating US politics and biotech. Are these immortality seekers gaining real power?

A Harvard professor's startup just got FDA approval for the world's first targeted human age reversal experiment. Silicon Valley has invested hundreds of millions in 'reprogramming' technology.

China could become the first market to approve a fully AI-designed drug in 2026, marking a seismic shift in pharmaceutical development as the country transforms from generic manufacturer to innovation powerhouse.

Discover why rare medical conditions are not just curiosities, but a biotech goldmine driving the future of gene editing, neurotech, and personalized medicine.

China is no longer a pharma copycat. With $1B R&D cycles and a massive data advantage, it's building a new global innovation engine. A PRISM analysis for investors.